Skip to main content

Helixgate

Skip to main content

Helixgate

Uncategorized

The next treatment-resistant depression paradigm

The next treatment-resistant depression paradigm

Published

on

In this episode of Denatured, you’ll hear from Hans Eriksson, chief medical officer at FundaMental Pharma and Steve Levine, chief patient officer at Compass Pathways. We explore why treatment-resistant depression remains so difficult to address, and how new approaches—from rapid-acting antidepressants to psychedelic therapy—may reshape the treatment paradigm.​ ​Read More

Continue Reading
Click to comment

Leave a Reply

Your email address will not be published. Required fields are marked *

Uncategorized

Replimune to ride wave of physician support to launch advanced melanoma therapy

Published

on

Analysts expect Replimune’s newly approved Tudriqev to reach $1.3 billion in peak sales in 2035.

Continue Reading

Uncategorized

‘Significant’ demand for Revolution drug; Intellia pinpoints liver toxicity culprit

Early indicators from a compassionate use plan led analysts to hike projections for daraxonrasib. Elsewhere, Intellia believes it’s answered a key safety question and Arrowhead moved to catch a rival.

Read More

Published

on

Early indicators from a compassionate use plan led analysts to hike projections for daraxonrasib. Elsewhere, Intellia believes it’s answered a key safety question and Arrowhead moved to catch a rival.

Read More

Continue Reading

Uncategorized

2026 Q2 Job Market Report: Job postings keep rising as fewer companies cut employees

Published

on

Job postings increase and competition dips, according to BioSpace data.

Continue Reading
Advertisement

Trending